Orlando Burgos Morales

Orlando Burgos Morales

Auto-generated profile, based on publicly available information

Orlando Burgos Morales

Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Materials Today Bio
Verified
Journal Article
Open access
OBO. Burgos-Morales
O. Burgos-Morales
MGM. Gueye
M. Gueye
LLL. Lacombe
L. Lacombe
CNC. Nowak
C. Nowak
RSR. Schmachtenberg
R. Schmachtenberg
WWWilfried Weber
Wilfried Weber
Materials in nature have fascinating properties that serve as a continuous source of inspiration for materials scientists. Accordingly, bio-mimetic and bio-inspired approaches have yielded remarkable structural and functional materials for a plethora of applications. Despite these advances, many properties of natural materials remain challenging or yet impossible to incorporate into synthetic materials. Natural materials are produced by living cells, which sense and process environmental cues and conditions by means of signaling and genetic programs, thereby controlling the biosynthesis, remodeling, functionalization, or degradation of the natural material. In this context, synthetic biology offers unique opportunities in materials sciences by providing direct access to the rational engineering of how a cell senses and processes environmental information and translates them into the properties and functions of materials. Here, we identify and review two main directions by which synthetic biology can be harnessed to provide new impulses for the biologization of the materials sciences: first, the engineering of cells to produce precursors for the subsequent synthesis of materials. This includes materials that are otherwise produced from petrochemical resources, but also materials where the bio-produced substances contribute unique properties and functions not existing in traditional materials. Second, engineered living materials that are formed or assembled by cells or in which cells contribute specific functions while remaining an integral part of the living composite material. We finally provide a perspective of future scientific directions of this promising area of research and discuss science policy that would be required to support research and development in this field.

17 September 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ACAlexia Carré
Alexia Carré
ZZZhicheng Zhou
Zhicheng Zhou
Javier Perez-HernandezJavier Perez-Hernandez
Javier Perez-Hernandez
FSFatoumata Samassa
Fatoumata Samassa
CLChristiana Lekka
Christiana Lekka
RMRoberto Mallone
Roberto Mallone
Interferon (IFN)-α is the earliest cytokine signature observed in individuals at risk for type 1 diabetes (T1D), but its effect on the repertoire of HLA Class I (HLA-I)-bound peptides presented by pancreatic β-cells is unknown. Using immunopeptidomics, we characterized the peptide/HLA-I presentation in in-vitro resting and IFN-α-exposed β-cells. IFN-α increased HLA-I expression and peptide presentation, including neo-sequences derived from alternative mRNA splicing, post-translational modifications - notably glutathionylation - and protein cis -splicing. This antigenic landscape relied on processing by both the constitutive and immune proteasome. The resting β-cell immunopeptidome was dominated by HLA-A-restricted ligands. However, IFN-α only marginally upregulated HLA-A and largely favored HLA-B, translating into a major increase in HLA-B-restricted peptides and into an increased activation of HLA-B-restricted vs. HLA-A-restricted CD8 + T-cells. A preferential HLA-B hyper-expression was also observed in the islets of T1D vs. non-diabetic donors, and we identified islet-infiltrating CD8 + T-cells from T1D donors reactive to HLA-B-restricted granule peptides. Thus, the inflammatory milieu of insulitis may skew the autoimmune response toward epitopes presented by HLA-B, hence recruiting a distinct T-cell repertoire that may be relevant to T1D pathogenesis.

19 June 2026 in Science Advances
Verified
Journal Article
Open access
OBOrlando Burgos-Morales
Orlando Burgos-Morales
FVFederica Vecchio
Federica Vecchio
FSFatoumata Samassa
Fatoumata Samassa
MPMargot Petit
Margot Petit
ZZZhicheng Zhou
Zhicheng Zhou
RMRoberto Mallone
Roberto Mallone
Coxsackieviruses B (CVBs) are plausible triggers of the pancreatic islet autoimmunity leading to type 1 diabetes. Islet autoantibody seroconversion correlates with persistent CVB infections in the gut and pancreas, suggesting defective antiviral control and the need to define immune mechanisms at the intestinal entry site. We investigated how CVB3 modulates antigen presentation, the viral immunopeptidome of enterocytes and antigen-presenting cells, and downstream T cell immunity. CVB3-infected enterocytes evaded immune recognition by down-regulating human leukocyte antigen (HLA) class I and viral peptide presentation, impairing CD8 + T cell responses in vitro. In CVB-seropositive individuals, circulating CVB-reactive CD8 + T cells were stalled in naïve-like and exhausted effector/memory states. In contrast, CVB3 induced HLA class II up-regulation, promoting robust CD4 + T cell activation. Circulating CVB3-reactive CD4 + T cells fully differentiated into polyfunctional T helper memory. These findings indicate that CVB3 antiviral control is predominantly CD4 + T cell mediated and provide a rationale for mucosal vaccination strategies and immune monitoring tools to follow infection or vaccination.

9 April 2026
Verified
Thesis
Closed access
OMOrlando Burgos Morales
Orlando Burgos Morales
Les Coxsackievirus déclenchent-ils un diabète de type 1 auto-immune ? : une étude immunopeptidomique: Le diabète de type 1 (DT1) est une maladie auto-immune causée par la destruction des cellules bêta pancréatiques productrices d'insuline par des lymphocytes T CD8+ (LT8) auto-réactifs. Des études ont mis en évidence un lien entre le DT1 et des infections persistantes par les coxsackievirus de type B (CVB). Ces virus infectent les cellules bêta et pénètrent dans l'organisme via l'épithélium intestinal. Des données histologiques et épidémiologiques montrent une forte association entre ces infections persistantes dans le pancréas et l'intestin et le développement du DT1. Notre groupe a récemment montré que les cellules bêta infectées par le CVB sont majoritairement détruites par le virus lui-même, et non efficacement ciblées par les LT8 anti-CVB. Nous émettons donc l'hypothèse que la persistance virale pourrait résulter d'une réponse T antivirale inefficace, favorisant l'auto-immunité par la libération d'auto-antigènes dans un contexte inflammatoire. Ce projet vise à déterminer si le CVB est capable d'échapper à la réponse immunitaire antivirale dès son site d'entrée intestinal. Pour cela, nous suivons les événements clés de cette réponse, en nous concentrant sur la présentation antigénique par les entérocytes infectés et par les cellules présentatrices d'antigène exposées aux cellules bêta infectées. Nous avons utilisé une approche d'immunopeptidomique basée sur la spectrométrie de masse pour identifier les peptides viraux présentés par les molécules HLA de classe I et II (HLA-I, HLA-II), à la fois dans un modèle d'infection entérocytaire (lignée CaCo2) et dans des macrophages dérivés de la lignée THP-1 exposés à des cellules bêta infectées. Ces peptides ont ensuite permis de suivre les réponses des lymphocytes T correspondants. Nos résultats montrent que le CVB déploie plusieurs stratégies d'évasion immunitaire dans les cellules CaCo2 : diminution de l'expression des HLA-I à la surface cellulaire, répertoire restreint de peptides viraux présentés, et propagation par filopodes. Cette faible exposition antigénique s'accompagne d'une perturbation des voies de présentation de l'antigène et d'une diminution des réponses aux interférons. En accord avec ce défaut de présentation via l'HLA-I, les LT8 réactifs à ces peptides présentent un phénotype effecteur/mémoire limité dans le sang de sujets séropositifs, et reconnaissent faiblement les cellules CaCo2 infectées in vitro. De manière intéressante, l'infection par le CVB induit une augmentation de l'expression des HLA-II, suggérant un rôle plus efficace des LT4 dans la réponse antivirale. Grâce aux peptides HLA-II identifiés, nous avons suivi les réponses CD4+ via des tests basés sur les marqueurs induits par l'activation. Ces résultats apportent un éclairage sur les mécanismes favorisant la persistance des infections à CVB. Ils pourront guider le développement de vaccins contre le CVB pour la prévention du DT1.

26 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
FVFederica Vecchio
Federica Vecchio
MPMargot Petit
Margot Petit
OBOrlando Burgos-Morales
Orlando Burgos-Morales
JLJutta Laiho
Jutta Laiho
MSMika Scheinin
Mika Scheinin
RMRoberto Mallone
Roberto Mallone
PRV-101 is a multivalent formalin-inactivated Coxsackievirus B (CVB) vaccine developed to prevent CVB infections, which are associated with increased risk of islet autoimmunity. While PRV-101 induces robust neutralizing antibody responses, its T-cell immunogenicity is unknown. We analyzed peripheral blood mononuclear cells from 25 healthy adults receiving three high or low PRV-101 doses or placebo in a Phase I randomized, placebo-controlled trial. CVB-reactive CD8⁺ T-cell responses were assessed using HLA Class I multimers, and CD4⁺ and T follicular helper (Tfh) responses were measured by activation-induced marker assays following stimulation with a CVB peptide library. PRV-101 elicited minimal CVB-reactive CD8⁺ T-cell responses but robust CD4⁺ and Tfh responses, peaking at week 12 and persisting through week 32. Responses were observed in both seronegative and seropositive individuals, consistent with effective immune priming and boosting. Tfh frequencies correlated with neutralizing antibody titers. Female participants exhibited higher peak Tfh responses than males. We conclude that PRV-101 elicits a CVB-protective immune profile, dominated by Tfh responses supporting durable humoral immunity and devoid of potentially diabetogenic cytotoxic T-cell responses. This profile invites further investigations in vaccine trials for type 1 diabetes prevention.